Related Experiment Videos
Superparamagnetic iron oxide-enhanced magnetic resonance imaging of experimental liver tumors after mitomycin C
O Clement1, G Frija, C Chambon
1Département de Radiologie, Hôpital Laennec, Université de Paris V, France.
Abstract:
The influence of mitomycin C chemotherapy on superparamagnetic iron oxide (SPIO) uptake by the liver was studied in rats (n = 70). This commonly used antineoplastic drug induces a decrease in the phagocytic function of the macrophage-phagocytic system (MPS). The plasma clearance of SPIO measured by relaxometry followed a biexponential model. The fast component half-life increased from 2.9 minutes in controls to 4.5 minutes in mitomycin C-treated animals. The slow component half-life increased from 11.3 to 36.7 minutes. Nevertheless, the magnetic resonance imaging (MRI) diagnostic efficacy 2 hours after infusion of the superparamagnetic agent AMI 25 (n = 10) was as satisfactory in the treated group as in the untreated one. These MRI results were consistent with the relaxometric T2* liver measurements, which were identical in both groups.
Insights
Mitomycin C chemotherapy reduced liver uptake of superparamagnetic iron oxide (SPIO) in rats by impairing macrophage function. However, diagnostic efficacy via MRI remained unaffected, indicating preserved imaging utility despite altered SPIO clearance.
Area of Science:
- Biomedical Imaging
- Pharmacology
- Radiology
Background:
- Superparamagnetic iron oxide (SPIO) nanoparticles are used as MRI contrast agents.
- Mitomycin C is a chemotherapy drug that affects the reticuloendothelial system.
- The impact of mitomycin C on SPIO liver uptake and MRI efficacy is not well understood.
Purpose of the Study:
- To investigate the influence of mitomycin C chemotherapy on SPIO uptake by the liver in a rat model.
- To assess the effect of mitomycin C on the plasma clearance kinetics of SPIO.
- To evaluate the diagnostic efficacy of MRI using SPIO contrast agents in mitomycin C-treated rats.
Main Methods:
- Rats (n=70) were treated with mitomycin C or served as controls.
- Plasma clearance of SPIO was measured using relaxometry.
- MRI scans were performed using AMI 25 in a subset of animals (n=10).
- Liver T2* measurements were obtained via relaxometry.
Main Results:
- Mitomycin C significantly decreased the phagocytic function of the macrophage-phagocytic system (MPS).
- Plasma clearance of SPIO showed prolonged fast and slow component half-lives in mitomycin C-treated rats.
- Despite altered SPIO kinetics, MRI diagnostic efficacy at 2 hours post-infusion was comparable between treated and untreated groups.
- Liver T2* measurements were identical in both groups.
Conclusions:
- Mitomycin C chemotherapy alters SPIO pharmacokinetics in rats by reducing MPS phagocytic activity.
- The diagnostic performance of MRI with SPIO contrast agents remains satisfactory in rats treated with mitomycin C.
- These findings suggest that MRI using SPIO agents can still be diagnostically effective in patients undergoing mitomycin C chemotherapy.